Microdosing GLP-1 medications like compounded tirzepatide and semaglutide means starting at doses well below standard prescribing guidelines — subject to medical approval by a licensed provider. TelosRX guides patients through a slow, individualized titration designed to minimize side effects while still supporting metabolic goals.
Most people abandon GLP-1s in the first two months. Not because the medication fails — because the side effects hit before the body adjusts. Nausea, fatigue, and GI distress at standard starting doses drive discontinuation. Microdosing is a protocol designed to prevent exactly that.
This step-by-step guide walks through how to microdose GLP-1 medications, who it's right for, and what a well-structured titration looks like when overseen by an asynchronous telehealth provider.
Step 1: Confirm You're a Candidate Before Starting
Microdosing is not a do-it-yourself protocol. Every step in this guide — including the decision to start at all — is subject to provider-issued prescription and medical evaluation.
Candidates tend to share a few characteristics:
- Previous GI intolerance to standard GLP-1 doses
- Metabolic goals that don't require rapid weight loss (e.g., blood sugar management, inflammation reduction)
- Weight maintenance after reaching a goal weight on a higher dose
- Interest in longevity-focused metabolic support rather than aggressive weight loss
- Perimenopause or hormone-related metabolic changes where gentler intervention is preferred
Contraindications include a personal or family history of medullary thyroid cancer, multiple endocrine neoplasia type 2, pancreatitis, or severe gastroparesis. Your provider's evaluation screens for all of these.
Step 2: Understand What "Microdose" Actually Means
There's no single universally agreed microdose definition. The term means any dose meaningfully below the standard prescribing range for weight loss. For context:
| Medication | Standard Starting Dose | Microdose Range (illustrative) | Maximum Approved Dose |
|---|---|---|---|
| Semaglutide (compounded) | 0.25 mg/week | 0.05–0.1 mg/week | 2.4 mg/week (Wegovy) |
| Tirzepatide (compounded) | 2.5 mg/week | 0.5–1 mg/week | 15 mg/week (Zepbound) |
These are illustrative ranges. Your actual dose is set by your licensed provider based on your health profile, goals, and response. Compounded versions of these medications are not FDA-approved and are prepared by licensed pharmacies under federal compounding regulations.
Step 3: Start at the Lowest Viable Dose (Weeks 1–2)
The first injection is deliberately conservative. For compounded semaglutide, a true microdose typically starts around 0.05–0.1 mg weekly — roughly half the standard starting dose. For compounded tirzepatide, 0.5–1 mg weekly is common at this level.
What to do during weeks 1–2:
- Inject on the same day each week, subcutaneously in the abdomen or thigh
- Stay well-hydrated — dehydration amplifies nausea
- Eat smaller, protein-forward meals; avoid high-fat, high-sugar meals right after injecting
- Note any GI symptoms, appetite changes, or fatigue in a simple log
Your provider reviews this feedback asynchronously — no real-time appointment required. TelosRX's asynchronous model means your care team reviews your updates on their schedule, typically within 24 hours.
Step 4: Assess Tolerance and Titrate Slowly (Weeks 3–6)
If you tolerated weeks 1–2 without significant symptoms, a small increase is appropriate. A typical two-step escalation looks like this:
| Week | Compounded Semaglutide | Compounded Tirzepatide | Assessment |
|---|---|---|---|
| 1–2 | 0.05–0.1 mg | 0.5–1 mg | Tolerance check |
| 3–4 | 0.1–0.15 mg | 1–1.5 mg | Appetite and GI response |
| 5–6 | 0.15–0.25 mg | 1.5–2.5 mg | Hold here if goals are being met |
The key principle: stay at the lowest dose that supports your goal. You do not need to chase the maximum dose. If you're losing one to two pounds per week or reaching your metabolic objectives at a low dose, that's where you stay.
For a deeper comparison of semaglutide and tirzepatide at different titration strategies, see Tirzepatide vs Semaglutide: Compounded GLP-1 Options Explained.
Step 5: Monitor Side Effects and Adjust in Real Time
Even at microdoses, some side effects can appear. The most common:
- Nausea — usually dose-dependent and mild at microdose levels; eating a light meal before injecting helps
- Constipation — increase fluid intake and dietary fiber; GLP-1s slow gastric emptying
- Fatigue or brain fog — often transient in the first 1–2 weeks; usually resolves with hydration and adequate caloric intake
- Appetite suppression — at microdoses, this may be subtle; that's the point for some patients
If symptoms are intolerable, your provider can hold the dose or reduce it. This is the primary advantage of a microdosing protocol: you're not locked into a rigid schedule. For a full breakdown of managing GLP-1 side effects, see GLP-1 Side Effects Management: What Research Shows.
Step 6: Establish Your Maintenance Dose
Many patients reach their goals before hitting standard prescribing doses. At that point, the protocol shifts to maintenance — staying on the lowest dose that preserves results without causing new side effects.
Some providers structure this as a gradual taper: reducing by one step per month until you find the floor that maintains results. Others prefer a fixed low dose indefinitely. The pharmacological principle is straightforward — GLP-1 receptor agonism at low doses still modulates appetite, glucose regulation, and inflammation, just less aggressively than full therapeutic doses.
Compounded GLP-1 medications offer dosing flexibility that brand-name products don't — one of the practical advantages of the compounded route.
Step 7: Ongoing Monitoring and Provider Check-Ins
Microdosing is not a "set it and forget it" protocol. Regular monitoring matters for two reasons: to confirm it's working, and to catch anything it isn't. A baseline metabolic panel is standard before starting. Follow-up labs — typically at 3 months — check for any changes in glucose regulation, kidney function, and lipids.
Through TelosRX's asynchronous telehealth model, you submit updates and lab results digitally. Your licensed provider reviews them and adjusts your protocol accordingly — no in-office visits required. All approvals are subject to evaluation by a licensed provider; approval is not guaranteed.
For patients considering GLP-1s for the first time alongside questions about GLP-1's impact on muscle preservation, see Muscle Loss on Semaglutide: Preserving Lean Mass on GLP-1.
How to Start a GLP-1 Microdosing Evaluation at TelosRX
TelosRX operates as an asynchronous telehealth service. You complete a health questionnaire, submit labs or have them ordered through the platform, and a licensed provider reviews your case and — if appropriate — issues a personalized compounded GLP-1 protocol. There are no real-time consultations required.
If you're interested in exploring this option, start your private evaluation at TelosRX.
Frequently Asked Questions
What is GLP-1 microdosing?
GLP-1 microdosing means using doses of GLP-1 receptor agonists — like compounded semaglutide or tirzepatide — that are significantly lower than standard prescribing guidelines. The goal is to access the metabolic benefits of GLP-1 therapy with fewer side effects. Any GLP-1 protocol requires a provider-issued prescription and medical evaluation.
Is microdosing GLP-1 effective for weight loss?
Microdosing may support gradual weight loss and metabolic health at doses below standard. Research on standard-dose semaglutide shows roughly 15% body weight reduction in controlled trials (Wilding et al., NEJM 2021). Microdose-specific outcomes are not yet established in large controlled trials. Individual results vary, and outcomes depend on dose, lifestyle, and patient factors.
What is the difference between microdosing semaglutide and tirzepatide?
Both are GLP-1 receptor agonists, but tirzepatide also activates GIP receptors (dual agonist). Tirzepatide's starting doses are higher in milligrams, so microdose ranges differ. Your provider determines the appropriate medication and dose based on your profile. Both compounded forms are not FDA-approved. See the full comparison here.
How long does it take to see results from GLP-1 microdosing?
At lower doses, results tend to come more gradually than at standard doses. Metabolic markers like fasting glucose and appetite regulation may improve within 4–8 weeks. Weight changes, if that's the goal, typically emerge over 2–4 months. Some patients use microdosing specifically for non-scale outcomes like reduced inflammation or blood sugar stability.
Can I stay on a microdose of GLP-1 long term?
Some patients do — particularly for weight maintenance after reaching a goal weight, or for ongoing metabolic support. Whether long-term low-dose GLP-1 use is right for you is determined by your provider based on ongoing labs and goals. No outcome is guaranteed, and protocols are reviewed regularly.
Does GLP-1 microdosing require a prescription?
Yes. Compounded GLP-1 medications are prescription medications and can only be dispensed following evaluation and approval by a licensed provider. TelosRX operates as an asynchronous telehealth service — you complete intake online, and a licensed provider reviews your case and determines candidacy.
What makes compounded GLP-1 microdosing different from branded medications?
Compounded GLP-1 medications allow for custom dosing increments that branded formulations don't offer — including the very low starting doses used in microdosing protocols. Compounded versions are not FDA-approved and are prepared under federal compounding regulations. They're dispensed only after evaluation by a licensed provider; approval is not guaranteed.
TelosRX is LegitScript-certified. Compounded medications are not FDA-approved and are prepared under federal compounding regulations. Approval is subject to evaluation by a licensed provider; approval is not guaranteed. Individual results vary. TelosRX operates as an online-first, asynchronous telehealth service.
Start your private evaluation at TelosRX.